These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 34713423)

  • 1. Incorporating Equity Concerns in Cost-Effectiveness Analyses: A Systematic Literature Review.
    Ward T; Mujica-Mota RE; Spencer AE; Medina-Lara A
    Pharmacoeconomics; 2022 Jan; 40(1):45-64. PubMed ID: 34713423
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distributional Cost-Effectiveness Analysis of Treatments for Non-Small Cell Lung Cancer: An Illustration of an Aggregate Analysis and its Key Drivers.
    Meunier A; Longworth L; Gomes M; Ramagopalan S; Garrison LP; Popat S
    Pharmacoeconomics; 2023 Aug; 41(8):1011-1025. PubMed ID: 37296369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eliciting Trade-Offs Between Equity and Efficiency: A Methodological Scoping Review.
    Cadham CJ; Prosser LA
    Value Health; 2023 Jun; 26(6):943-952. PubMed ID: 36805575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Balancing costs and benefits at different stages of medical innovation: a systematic review of Multi-criteria decision analysis (MCDA).
    Wahlster P; Goetghebeur M; Kriza C; Niederländer C; Kolominsky-Rabas P;
    BMC Health Serv Res; 2015 Jul; 15():262. PubMed ID: 26152122
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Challenges and Limitations in Distributional Cost-Effectiveness Analysis: A Systematic Literature Review.
    Steijger D; Chatterjee C; Groot W; Pavlova M
    Int J Environ Res Public Health; 2022 Dec; 20(1):. PubMed ID: 36612824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Accounting for equity considerations in cost-effectiveness analysis: a systematic review of rotavirus vaccine in low- and middle-income countries.
    Boujaoude MA; Mirelman AJ; Dalziel K; Carvalho N
    Cost Eff Resour Alloc; 2018; 16():18. PubMed ID: 29796012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrating social justice concerns into economic evaluation for healthcare and public health: A systematic review.
    Dukhanin V; Searle A; Zwerling A; Dowdy DW; Taylor HA; Merritt MW
    Soc Sci Med; 2018 Feb; 198():27-35. PubMed ID: 29274616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distributional cost-effectiveness analysis in low- and middle-income countries: illustrative example of rotavirus vaccination in Ethiopia.
    Dawkins BR; Mirelman AJ; Asaria M; Johansson KA; Cookson RA
    Health Policy Plan; 2018 Apr; 33(3):456-463. PubMed ID: 29309581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinical effectiveness and cost-effectiveness of home-based, nurse-led health promotion for older people: a systematic review.
    Tappenden P; Campbell F; Rawdin A; Wong R; Kalita N
    Health Technol Assess; 2012; 16(20):1-72. PubMed ID: 22490205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk management frameworks for human health and environmental risks.
    Jardine C; Hrudey S; Shortreed J; Craig L; Krewski D; Furgal C; McColl S
    J Toxicol Environ Health B Crit Rev; 2003; 6(6):569-720. PubMed ID: 14698953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can cost-effectiveness analysis integrate concerns for equity? Systematic review.
    Johri M; Norheim OF
    Int J Technol Assess Health Care; 2012 Apr; 28(2):125-32. PubMed ID: 22494637
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generalisability in economic evaluation studies in healthcare: a review and case studies.
    Sculpher MJ; Pang FS; Manca A; Drummond MF; Golder S; Urdahl H; Davies LM; Eastwood A
    Health Technol Assess; 2004 Dec; 8(49):iii-iv, 1-192. PubMed ID: 15544708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reconciling ACEA and MCDA: is there a way forward for measuring cost-effectiveness in the U.S. healthcare setting?
    Zamora B; Garrison LP; Unuigbe A; Towse A
    Cost Eff Resour Alloc; 2021 Mar; 19(1):13. PubMed ID: 33648523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distributional Cost-Effectiveness Analysis of Health Technologies: Data Requirements and Challenges.
    Meunier A; Longworth L; Kowal S; Ramagopalan S; Love-Koh J; Griffin S
    Value Health; 2023 Jan; 26(1):60-63. PubMed ID: 35941004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Equity and economic evaluation of system-level health interventions: A case study of Brazil's Family Health Program.
    Love-Koh J; Mirelman A; Suhrcke M
    Health Policy Plan; 2021 Apr; 36(3):229-238. PubMed ID: 33386400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eliciting public preferences for healthcare: a systematic review of techniques.
    Ryan M; Scott DA; Reeves C; Bate A; van Teijlingen ER; Russell EM; Napper M; Robb CM
    Health Technol Assess; 2001; 5(5):1-186. PubMed ID: 11262422
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 19.